Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Hold” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned an average rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $6.75.

A number of equities research analysts have commented on INO shares. Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its holdings in Inovio Pharmaceuticals by 1,929.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 46,536 shares during the period. Virtu Financial LLC purchased a new position in shares of Inovio Pharmaceuticals during the 4th quarter valued at about $77,000. Janus Henderson Group PLC grew its stake in shares of Inovio Pharmaceuticals by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock valued at $5,773,000 after acquiring an additional 42,146 shares during the period. Bridgeway Capital Management LLC bought a new position in Inovio Pharmaceuticals in the 4th quarter worth $301,000. Finally, 683 Capital Management LLC purchased a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth about $433,000. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals News Roundup

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright issues an optimistic outlook for INO’s Q1 results, which could support sentiment if the company posts stronger-than-expected metrics. HC Wainwright Has Optimistic Outlook of INO Q1 Earnings
• Neutral Sentiment: Investors can review Inovio’s Q4 2025 earnings call transcript for detail on recent results and management commentary that may affect forward guidance and cash runway. Q4 2025 earnings call transcript
• Negative Sentiment: Multiple law firms have publicized a securities class action against Inovio (class period: Oct 10, 2023–Dec 26, 2025) and are soliciting lead-plaintiff candidates ahead of an April 7, 2026 deadline — increasing the likelihood of continued legal overhang, litigation costs and distraction for management. Representative notices include Pomerantz and Rosen. Pomerantz class action filing
• Negative Sentiment: Several additional firms (Faruqi & Faruqi, The Gross Law Firm, Glancy Prongay Wolke, Bronstein Gewirtz & Grossman, Schall Law Firm) have issued shareholder alerts about the same litigation and the April 7 deadline, amplifying media attention and potential plaintiff coordination. Faruqi & Faruqi investor notice
• Negative Sentiment: Coverage in financial press flags alleged disclosure issues around Inovio’s vaccine candidates, which is the basis for the shareholder suit and could prompt regulatory scrutiny or increased reputational risk. Inovio faces shareholder lawsuit article

Inovio Pharmaceuticals Trading Down 4.2%

Shares of INO opened at $1.58 on Monday. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $2.98. The firm’s 50-day moving average price is $1.65 and its 200-day moving average price is $2.03. The firm has a market capitalization of $109.16 million, a price-to-earnings ratio of -0.94 and a beta of 1.70.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.68. The business had revenue of ($0.07) million for the quarter, compared to the consensus estimate of $0.33 million. On average, research analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.